FDA approves Merck's rare PAH drug at center of $11.5B Acceleron deal
The FDA on Tuesday cleared Merck’s pulmonary arterial hypertension treatment, which could quickly become a blockbuster for the New Jersey pharma giant.
Merck will market sotatercept as Winrevair.
The condition impacts about 40,000 people in the US, and about 43% of patients die within five years of diagnosis, said Eliav Barr, chief medical officer at Merck Research Laboratories, in an interview with Endpoints News before the approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
